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Introduction
Sarcoidosis is a multisystemic granulomatous disease of
unknown etiology in which environmental exposures are
believed to interact with genetic factors in determining the
pattern of sarcoidosis presentation, progression and prog-
nosis [1–3]. The consensus is that the disease results from
an exaggerated cellular immune response (acquired, inher-
ited or both) to a limited class of antigens or self-antigens
[1,3]. Disease activity is accompanied by mononuclear cell
infiltrates and granuloma formation, the most common
organs involved being the lung and lymph nodes, although
almost any organ can be affected, including the eyes, heart,
skin and the central nervous system. The course and prog-
nosis of the disease are correlated with the mode of onset,
where an acute onset accompanied by fever, arthralgia and
erythema nodosum (sarcoid arthritis, Löfgren syndrome
[4]) usually heralds a self-limited course with spontaneous
resolution, whereas an insidious onset may be followed by
chronic disease with relentless, progressive fibrosis [1,3].
For an individual patient, however, only time and close
observation will provide a specific answer regarding the
disease course, making an appropriate treatment with
respect to disease manifestation at the time of disease
diagnosis difficult. Although many attempts to find prog-
nostic markers for a better assessment of sarcoidosis and
to ameliorate treatment of patients have been made, a reli-
able marker is still lacking [1,3,5].
Granulomatous reactions have been shown to be regu-
lated by numerous endogenous mediators, of which the
immunoregulatory cytokine TNF-α is thought to play a
pivotal role. In sarcoidosis, the presence of TNF-α mRNA
transcripts and protein in granulomas has been reported
[6] and, interestingly, TNF-α mRNA levels were shown to
be increased in sarcoid granulomas in lymph nodes com-
pared with control lymph nodes from patients with local-
ized primary lung carcinoma [7]. On the cellular level,
elevated spontaneous and induced ex vivo release of
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TNF-α is observed by alveolar macrophages of sarcoido-
sis patients [8–10]. Furthermore, the individual capacity of
the patient to release TNF-α from alveolar macrophages is
a phenomenon linked with active and progressive disease,
implying that this cytokine plays a role in the pathogenesis
of sarcoidosis [9] and may even represent a candidate
marker for determining the course of the disease [11].
Because of the important role of TNF-α as a central
immunomodulator and mediator of granuloma formation,
and since elevated TNF-α levels are typically found during
active phases of sarcoidosis, genetic polymorphisms cor-
relating with influences on TNF-α levels appear to be of
special interest in the context of disease pathology. A
number of different polymorphisms in the MHC locus have
been shown to be associated with variations in TNF-α pro-
duction and to be associated with predisposition to and
disease presentation of sarcoidosis. These investigations,
and others examining genetic polymorphisms not located
in the MHC locus, imply that it is unlikely one gene locus is
responsible for predisposition to and clinical outcome of
the disease. It rather seems that multiple genetic factors
may be involved, perhaps constituting an extended
disease-associated haplotype.
The complete sequencing of the MHC region and the
increase in the number of identified gene polymorphisms
in this locus associated with TNF-α production offer the
opportunity of detecting new genes associated with sar-
coidosis, and perhaps of defining disease-associated hap-
lotypes. This is discussed in the context of the authors’
own data and published data, with the focus on the TNF
and human leukocyte antigen (HLA)-DR gene loci that
indicate such a hypothetical disease-associated haplotype
is a probability. A correlation of haplotypes with the clinical
presentation and outcome of sarcoidosis bear the poten-
tial of serving as predictive markers for this disease and
may even show to be of prognostic value, a prerequisite
for improving treatment regimes of patients suffering from
this elusive disease.
Genetic determinants of TNF-α α production
and correlations to disease
TNF-α is an inducible cytokine with a broad range of pro-
inflammatory and immunostimulatory actions, and it is
thought to play a fundamental role in many diseases. It is
classified as an early response mediator since it may be
released in copious amounts by TNF-α-producing cells on
stimulation, which in turn set into motion a cascade of
events leading to the development of cytokine networks
important in orchestrating an inflammatory response.
Variation in TNF-α production level is an innate host char-
acteristic that was shown to vary between individuals and
to be associated with certain HLA-DR alleles [12,13]. The
TNF gene locus, comprising the TNF-α, lymphotoxin-α
(formerly TNF-β) and lymphotoxin-β genes, is located in
the class III region of the MHC, telomeric to the class II
region and centromeric to the class I region. Genetic
analysis has revealed a number of polymorphisms in these
genes, and new polymorphisms with potential functional
consequences continue to be discovered [14].
The MHC III region contains other genes than TNF that
are becoming increasingly interesting with respect to
autoimmune and infectious diseases since they encode
for proteins involved in immune and inflammatory
responses [15]. These genes include, for instance, the
allograft inflammatory factor 1, the leukocyte-specific
transcript 1, IKBL (NFKBIL1), BAT1 and the immunoglob-
ulin superfamily gene member 1C7. The most extensive
data, however, have accumulated on two of the most
studied polymorphisms in the TNF locus (the biallelic
polymorphisms at position –308 in the promoter region of
the TNF-α gene and in the first intron of the lymphotoxin-
α gene), both of which have been associated with varia-
tion in TNF-α production and with susceptibility to
infectious and autoimmune diseases [14]. Moreover,
these two polymorphisms have been found to be strongly
associated with the polymorphic MHC 8.1 (A1, B8, DR3)
ancestral haplotype [16,17], which is associated not only
with multiple immunopathological diseases [18], but also
with variations in TNF-α production [16]. Given these
findings, the genetic background of an individual may
thus predispose for production levels of TNF-α and, given
the importance of this immunomodulating cytokine, this
may influence the immune response and thus, finally, the
clinical course of disease.
Gene polymorphisms implicated in
susceptibility to sarcoidosis
Evidence for genetic predisposition for sarcoidosis has
long been assumed due to the prevalence of the disease
in different ethnic groups and due to familial occurrence
[2,3]. It is believed that a supposed genetic susceptibility
is most probably conferred by more than one immune reg-
ulatory gene, which act synergistically on disease risk.
Numerous studies have been performed to clarify this
aspect [2] and, especially, the highly polymorphic HLA
locus has been investigated intensely. The findings for
HLA associations have not been consistent, however,
because of differences in the HLA allele distribution in dif-
ferent ethnicities [19] and because of additional suscepti-
bility genes adjacent to or within the MHC.
First reports examining other genes in the MHC have also
not conclusively found an association with susceptibility to
sarcoidosis, as shown for example for the transporter
associated with antigen processing (TAP2) or the latent
membrane protein 1 gene in the Japanese (no associa-
tion) [20,21], and complement protein C4A, C4B and
factor B in Caucasians (no association) [22]. A secondPage 3 of 6
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investigation on TAP1 and TAP2 in Caucasians based on
two different ethnic patient/control groups from the UK
and Poland found significant differences in TAP2 when
comparing the respective ethnic case–control groups
[23]. An interesting point of this study was, however, that
on comparing UK and Polish control groups, significant
differences were found in TAP1 and additional differences
were found between the two patient groups concerning
TAP2, indicating that the use of multiple defined ethnic
populations may help with, and should be considered in,
defining the role of genetic factors in sarcoidosis [24].
A recent investigation on 122 affected siblings from 55
families resulted in data showing highly significant evi-
dence for the involvement of genes of the MHC region for
genetic predisposition to sarcoidosis. The analysis sug-
gested that no single gene may account for the significant
results but, rather, that multiple additive MHC gene
effects, possibly some of them in linkage disequilibrium,
may be considered in conferring susceptibility to sarcoido-
sis [24]. Moreover, a genome wide scan performed by the
same group confirmed and significantly underlined the
major involvement of the MHC locus in which this major
association was found besides six minor associations on
five different chromosomes [25], substantiating the
hypothesis that multiple genes may be involved in suscep-
tibility to the disease.
Apart from genes of the MHC locus, other genes with a
putative influence on susceptibility to sarcoidosis have
been investigated. For example, the insertion/deletion
polymorphism of the angiotensin-converting enzyme gene
(I/D ACE), which is interesting because it correlates with
variations in serum angiotensin-converting enzyme levels,
in turn used as a disease activity marker in sarcoidosis,
has been shown to correlate with disease progression in
African Americans [26], to be significantly increased in
Scandinavian patients with autoimmune manifestations
[27], and to be associated with poor prognosis in Finns
[28]. On the contrary, Arbustini et al. found no association
in Caucasians [29], and no association was found in other
Japanese cohorts [30,31]. A further study in Caucasians
raises the question whether this I/D ACE polymorphism
may rather be involved in the clinical manifestation of the
disease, since it was not found to be an inherited main
cause of sarcoidosis [32].
Overall, these various investigations with disparate results
demonstrate that genetic susceptibility to sarcoidosis is
multigenetic and that ethnicity should be considered. In
addition, an important aspect to keep in mind with respect
to genetic studies is environmental effects such as could
be demonstrated by epidemiological studies in Japan and
Iceland, where a homogeneous genetic background of the
indiginous population is assumed [33,34]. For instance,
the subpolar climate in contrast to the moderate or sub-
tropical climate on the Japanese islands increases sar-
coidosis incidence in a Japanese population [33]; also, in
Iceland, exposure to cristobalite leads to an increase in
sarcoidosis incidence [34]. These findings give rise to the
hypothesis that sarcoidosis is multigenetic and multifactor-
ial in nature.
A further factor to be considered is the heterogeneity of
patient groups used in the different studies with respect to
the relative proportions of the different clinical manifesta-
tions of the disease in different cohorts, which could influ-
ence the results of case–control studies. The fact that
environmental phenocopies of sarcidosis exist compli-
cates its genetic analysis. Berylliosis, an occupational dis-
order seen in up to 5% of beryllium-exposed workers, is a
complete phenocopy of sarcoidosis with a distinct sus-
ceptibility locus in the MHC II, the HLA-DPB Glu69+
allele [35]. Moreover, other anorganic compounds (zirco-
nium, aluminum, cristobalite [36]) or even bioaerosols [37]
might cause the manifestation of granulomatous disorders
presenting as phenocopies of sarcoidosis [38]. These
considerations support the notion that sarcoid-like granu-
loma formation represents a final immunopathological
pathway induced by different biological agents [1].
Genetic factors as potential predictive
markers in sarcoidosis
Apart from contributing to susceptibility to sarcoidosis, it
is also probable that genetic factors may be important in
defining the pattern of disease presentation and progres-
sion as well as its overall prognosis.
Early indications for the involvement of inherited host
factors influencing the clinical expression of sarcoidosis
were reported by Smith et al. [39], who showed that HLA-
B8 significantly correlates with resolution of the disease.
In fact, the association of the B8-DR3 genotype has since
been associated with good prognosis in a number of
studies [40,41]. An association of HLA-DR3 was also
found with acute onset of disease (sarcoid arthritis,
Löfgren syndrome) in a series of investigations [40,42,43].
This is remarkable in conjunction with the aforementioned
studies since acute onset of sarcoidosis usually leads to
resolution of disease and is thus considered a sign for
good prognosis. In this setting, an interesting finding was
that the TNFA2 allele, which is in strong linkage disequilib-
rium with HLA-DR3 [17], was also shown to significantly
correlate with Löfgren syndrome [44]. HLA-DR3 also
showed additional correlations with resistance to severe,
long-standing disease and predisposition to spontaneous
remission [45] and good outcome [46]. A 10-year
prospective study substantiated these previous observa-
tions by showing a correlation of DR3 with good progno-
sis and DR2 with chronic disease, thus propagating
HLA-DR typing as a prognostic tool in predicting the
outcome of disease [5].
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TNFA2 allele may contribute to associations of this haplo-
type. We therefore investigated both the HLA-DR and TNF
loci in patients with sarcoidosis [47]. The results demon-
strated that this genetic analysis clearly discriminated
patients exhibiting Löfgren syndrome from sarcoidosis
patients not presenting with this syndrome and thus being
more prone to developing chronic disease. It was found
that, in the Löfgren syndrome patient group, the TNFA2
and the HLA-DR3 alleles were represented significantly
more, with a highly significant relative risk for developing
Löfgren syndrome associated with the possession of the
TNFA2 or HLA-DR3 allele, or of both alleles. In the non-
Löfgren syndrome patient group, the phenotype expressing
HLA-DR2 and lacking TNFA2 was represented signifi-
cantly higher than in the Löfgren syndrome patient group.
Only the genotyping of both the TNFA and the HLA-DR
locus (combined genotypes) allowed the discrimination
between the two sarcoidosis patient subgroups of Löfgren
syndrome and non-Löfgren syndrome [47]. Interestingly,
both DR3 and TNFA2 are correlated with increased TNF-
α levels, and DR2 and TNFA1 are correlated with lower
TNF-α production levels [13,48]. The results of this com-
bined genetic analysis thus imply that genetic predisposi-
tion for TNF-α production may play a role in the
pathogenesis of sarcoidosis.
Supplementary statistical analysis of these published
patient data [47] was recently performed to resolve which
allele confers the greater risk (TNFA or HLA-DR) for
expression of either disease phenotype and to determine
whether disease haplotypes in correlation to the different
disease courses can be defined [49]. The results essen-
tially demonstrated that it seems very probable, with
respect to this patient group and the discrimination
between presentation with or without Löfgren syndrome,
that the risk for developing or not developing Löfgren syn-
drome is conferred not by these two genetic traits alone,
but that other elements possibly in linkage disequilibrium
might contribute to the development of these different
disease phenotypes. In addition, the construction of virtual
haplotypes by means of a statistical calculation [49]
showed that the DR3.TNFA2 haplotype was significantly
associated with Löfgren syndrome and that the
DR2.TNFA1 haplotype was associated with the non-
Löfgren syndrome patients, giving substance to the
hypothesis that haplotypes, rather than single genes inter-
acting with each other, are a highly probable explanation
for these correlations.
As a consequence, genetic analyses may have the poten-
tial of discriminating sarcoidosis patient subsets accord-
ing to the clinical course of disease. The use of applying
these genetic traits as predictive and potential prognostic
markers in sarcoidosis must of course be substantiated
and investigated in prospective studies since, for example,
although Löfgren syndrome usually heralds a self-limiting
course of sarcoidosis with spontaneous resolution, recur-
rences may occasionally occur and may even develop into
chronic sarcoidosis of the lung [3,4].
Questions addressed in this context were whether geno-
types shown in the literature to be related to higher TNF-α
production levels [14] lead to higher TNF-α levels in a
disease setting, and whether assessment of TNF-α levels
is of prognostic value. For the latter aspect, a study was
performed in which patients were divided into a group
with and a group without indications for therapy, with eval-
uation of disease course and measurement of release of
TNF-α from cultured alveolar macrophages approximately
6 months after diagnosis [11]. Interestingly, despite both
patient groups having significantly higher TNF-α levels
compared with controls, patients without indications for
therapy with a high level of TNF-α release had a signifi-
cantly greater risk of disease progression than did those
with normal TNF-α release. This finding thus sets a case
for TNF-α release being a suitable parameter for predict-
ing disease course, but with high levels correlating with
disease progression, which seems to stand in contradic-
tion to the genotyping findings. Since genotyping data for
these patient groups were not obtained and since the
patient cohorts differ, however, no direct comparison can
be made to resolve this apparent contradiction.
A further study correlated TNF-α levels with TNF geno-
types in a sarcoidosis patient cohort [10]. Although no
significant differences in TNF-α release were found
between carriers and non-carriers of alleles correlated
with higher TNF-α production, there was nonetheless a
trend to higher production levels in carriers of the TNFA2
allele. This patient cohort again differed from that in which
the correlation with Löfgren syndrome and TNFA2/HLA-
DR3 was established. In addition, the cohort did not
include patients with Löfgren syndrome and only one of
44 patients was TNFA2 homozygous (in contrast to eight
of 101 in the former study). A major question that thus
remains to be resolved is whether the correlations on the
genetic level of alleles associated with TNF-α production
with disease course in sarcoidosis are in any way reflected
by correlations with actual TNF-α production levels. Since
investigations performed to find correlations of TNF-
relevant gene polymorphisms with TNF-α production
levels have also not produced clear cut results [14], it may
well be that in this case multiple genetic factors acting in
concert must also be considered.
Studies performed in Japanese patients with sarcoidosis
further complicate the matter. Two recent studies have
also shown correlations with sarcoidosis disease pheno-
types and gene polymorphisms implicated in TNF-α pro-
duction levels. In one study, the TNFA2 allele, associated
Respiratory Research    Vol 3 No 1 Seitzer et al.
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icantly associated with cardiac sarcoidosis, implicating a
role for this allele in developing this more severe form of
the disease [50].
Yamaguchi et al. [51] performed a first prognostic study
on 110 patients with a mean follow-up period of 67
months to evaluate the potential prognostic value of the
TNFA and TNFB polymorphisms. Interestingly, in this
cohort, which consisted of patients with a relatively benign
course not requiring corticosteroid therapy, a significant
correlation with prolonged disease course was found with
the TNFB1 allele. Since TNFB1 is in strong linkage dis-
equilibrium to TNFA2 and correlates with high TNF-α pro-
duction levels, these results stand somewhat in
contradiction to the analyses correlating TNFA2 with a
benign disease course.
Despite the fact that the correlations found with TNFA2
were not performed in a prognostic study, however, one
should consider the different patient groups both with
respect to the ethnic background and the disease pheno-
types involved. It is striking, for instance, that in the Japan-
ese control group the TNFA allele frequency
(TNFA1/TNFA2, 0.99/0.01 [51]) differs markedly from
that of the Caucasian control group (TNFA1/TNFA2,
0.81/0.19 [44]), and that HLA-DR3 specificities (in strong
linkage with TNFA2) in Caucasian and Asian populations
also markedly differ (Asian, 0.05; Caucasian, 0.10 [19]),
indicating that a direct comparison of these differing
results is not possible. In conclusion, however, all these
studies provide evidence for the assumption that gene
polymorphisms influencing TNF-α production levels con-
tribute to disease course in addition to determining sus-
ceptibility to sarcoidosis.
Concluding remarks
In summary, data from the literature indicate that genetic
polymorphisms play a role in regulating TNF-α levels,
which in turn may influence the immune response of an
individual and, finally, the course and outcome of diseases.
It appears very probable that different polymorphisms
shown to correlate with TNF-α production, and possibly
new genetic traits not yet defined, act synergistically on
TNF-α production levels. This statement is also underlined
by the fact that, for instance, investigations on variations in
TNF-α production in correlation with the –308 TNF gene
polymorphism have given disparate results, therefore
implying that more than one genetic factor may be
involved in potentiating effects.
A first point to consider in searching for additional genes
influencing TNF-α production is to look for genes in strong
linkage disequilibrium, as for instance HLA-DR3, but other
genes have also been described and should be taken into
consideration [14]. In addition, the availability of sequence
data of the MHC [52], in which the important genes perti-
nent to TNF-α production are localized, holds the promise
of discovering new polymorphisms influencing TNF-α pro-
duction and thus potentially playing a role in disease sus-
ceptibility and disease course. The application of new
technologies (DNA arrays) combined with new insights
into gene linkages, single nucleotide polymorphisms and
extended haplotypes of the MHC may aid in closer defin-
ing genetic influences on TNF-α production.
With respect to defining disease course in sarcoidosis in
correlation with genetic traits, the summary presented
implies that it may be worthwhile to investigate TNF-α-
relevant polymorphisms for two reasons. First, since the
MHC locus in which the TNF genes are located has
recently been shown to be the most significant locus
associated with sarcoidosis [24,25] and, second, since
two MHC loci alone (HLA-DR and TNFA) already allow a
significant discrimination between two patient subgroups
to be made [47,49], thus holding the promise of function-
ing as potential predictive markers and perhaps in defining
clinical subsets for this disease.
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